A meta-analysis of montelukast for recurrent wheeze in preschool children

Hasan R Hussein1,2, Atul Gupta1,2, Simon Broughton1

  • 1Faculty of Life Sciences & Medicine, Kings College London, London, UK.

Insights

Montelukast is not effective for treating preschool wheeze, failing to prevent episodes or reduce medical visits. Further research is needed to identify potential

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Conflicting evidence exists regarding montelukast's effectiveness in preschool wheeze.
  • Previous reviews focused on viral-induced wheeze, a subgroup with limited real-world applicability.
  • International consensus highlights the evolving nature of wheeze phenotypes in young children.

Purpose of the Study:

  • To investigate the efficacy of montelukast in all children diagnosed with preschool wheeze.
  • To evaluate montelukast's impact on wheezing episodes, unscheduled medical attendances, and oral corticosteroid use.
  • To synthesize evidence from randomized controlled trials comparing montelukast with placebo.

Main Methods:

  • Systematic screening of PubMed, Cochrane Library, Ovid Medline, and Ovid EMBASE for relevant randomized controlled trials (RCTs).
  • Inclusion criteria focused on children with recurrent preschool wheeze treated with montelukast versus placebo.
  • Primary endpoint was the frequency of wheezing episodes; secondary endpoints included unscheduled medical attendances and oral corticosteroid use.

Main Results:

  • Meta-analysis of intermittent montelukast showed no significant benefit in preventing wheeze episodes (MD 0.07, p=0.5).
  • Montelukast did not significantly reduce unscheduled medical attendances (MD -0.13, p=0.21) or oral corticosteroid use (MD -0.06, p=0.25).
  • Continuous montelukast regimens also showed no significant difference in wheezing episodes compared to placebo (MD -0.40, p=0.18).

Conclusions:

  • Current evidence does not support the use of montelukast for preschool children experiencing recurrent wheeze.
  • The study suggests that a specific 'montelukast responder' phenotype may exist but requires further investigation.
  • Larger multicenter RCTs are recommended to identify and characterize potential montelukast responders in clinical practice.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.4K